REG - BioPharma Credit PLC - UPDATE ON INVESTMENT

Biopharma CreditAnnouncement

Mon 13:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260302:nRSB9734Ua&default-theme=true

RNS Number : 9734U  BioPharma Credit PLC  02 March 2026

2 March 2026

 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

UPDATE ON INVESTMENT

 

New Increased Loan Agreement with UroGen

 

The Company notes the announcement released on 2 March 2026 by UroGen Pharma
Ltd. ("URGN"), regarding the second amendment and restatement of its loan
agreement with the Company, BioPharma Credit Investments V (Master) LP
("BioPharma-V"), and BPCR Limited Partnership (the "2(nd) A&R Loan
Agreement").

 

The Company had previously announced on 15 March 2024 the first amendment and
restatement of its senior secured loan agreement with URGN (the "Existing Loan
Agreement"). Under the 2(nd) A&R Loan Agreement, the existing US$125
million senior secured loan was increased to US$200 million in a new Tranche A
(with the additional US$75 million being funded at closing), and an additional
Tranche B was added for up to US$50 million for a total new senior secured
loan facility of up to US$250 million.

 

The Company has a 50 per cent. allocation to each tranche with BioPharma-V
receiving the remaining (and equal) allocation. The Company therefore has an
allocation of US$100 million of Tranche A (increased from US$50 million
investment under the Existing Loan Agreement) and US$25 million of Tranche B.

 

The new Tranche B of up to US$50 million is available to be drawn by 30 June
2027, subject to customary conditions precedent set forth in the 2(nd) A&R
Loan Agreement. Under the 2(nd) A&R Loan Agreement, the interest rate is a
fixed 8.25 per cent. per annum. A one-time additional consideration of 1.50
per cent. of each new tranche is payable by URGN upon funding of each
respective tranche, with the Company therefore receiving US$1.5 million (of a
US$3.0 million payment) in connection with the new Tranche A on the signing of
the 2(nd) A&R Loan Agreement. In addition, an exit fee of 1.00 per cent is
also required upon any payment of principal, scheduled or otherwise.

 

In connection with entering into the 2(nd) A&R Loan Agreement, URGN paid
US$8.6 million in make-whole and prepayment fees, and accrued interest under
the Existing Loan Agreement, of which the Company received US$3.0 million.

 

URGN is a publicly traded biopharmaceutical company focused on developing
products to treat specialty cancers and urologic diseases with a current
market capitalization of ~US$935 million (Ticker: URGN - NASDAQ).  URGN
currently markets Jelmyto® (mitomycin) pyelocalyceal solution, the first
FDA-approved product for low-grade upper tract urothelial carcinoma (LG-UTUC)
and Zusduri® (mitomycin) intravesical solution, FDA-approved for post-surgery
low-grade bladder cancer (LG-IR-NMIBC). URGN reported US$109.8 million in
revenues in 2025 (up 21.4% per cent. from 2024).

 

Enquiries:

 

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

 

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDJTMJTMTJMBPF



            Copyright 2019 Regulatory News Service, all rights reserved